Abstract Purpose: The presence of intrinsic radiosensitivity within prostate cancer patients may be an important factor contributing to development of radiation toxicity. We investigated whether variants in genes responsible for detecting and repairing DNA damage independently contribute to toxicity following prostate brachytherapy. Experimental Design: Genomic DNA was extracted from blood samples of 41prostate brachytherapy patients, 21 with high and 20 with low late toxicity scores. For each patient, 242 PCR amplicons were generated containing 173 exons of eight candidate genes: ATM, BRCA1, ERCC2, H2AFX, LIG4, MDC1, MRE11A, and RAD50. These amplicons were sequenced and all sequence variants were subjected to statistical analysis to identify those associated with late radiation toxicity. Results: Across 41 patients, 239 sites differed from the human genome reference sequence; 170 of these corresponded to known polymorphisms. Sixty variants, 14 of them novel, affected protein coding regions and 43 of these were missense mutations. In our patient population, the high toxicity group was enriched for individuals with at least one LIG4 coding variant (P = 0.028). One synonymous variant in MDC1, rs28986317, was associated with increased radiosensitivity (P = 0.048). A missense variant in ATM, rs1800057, associated with increased prostate cancer risk, was found exclusively in two high toxicity patients but did not reach statistical significance for association with radiosensitivity (P = 0.488). Conclusions: Our data revealed new germ-line sequence variants, indicating that existing sequence databases do not fully represent the full extent of sequence variation. Variants in three DNA repair genes were linked to increased radiosensitivity but require validation in larger populations.
Prostate brachytherapy is a standard treatment for early-stage prostate cancer. Radioactive seeds are implanted into the prostate to deliver high doses of highly conformal radiation achieving excellent long-term results (1 -3) . Due to widespread use of prostate-specific antigen screening, the incidence of prostate cancer has increased, and the age at diagnosis has shifted toward younger men. Toxicity due to radiation exposure of surrounding normal tissue includes acute and late urinary toxicity, acute and late rectal toxicity, and loss of sexual potency. Predictive clinical factors for severity of toxicity, such as baseline urinary and sexual function before procedure and radiation dose, have been investigated by our group (3 -9) and others (10 -12) , but overall there is no consensus that any of these factors are effective predictors of late side effects of prostate brachytherapy.
The presence of intrinsic radiosensitivity may prove to be an important factor contributing to development of prostate brachytherapy toxicity. Several observations support the hypothesis that an individual's radiosensitivity is mediated by genetic features. Radiosensitivity appears to be an inherited trait, as monozygotic twins have greater intrapair correlation of response than dizygotic twins (13) and two studies of breast cancer patients have found that cells from first-degree relatives of patients with high radiosensitivity are similarly sensitive to radiation (14, 15) . Ionizing radiation such as that used in prostate brachytherapy has been well documented to cause double-stranded breaks (DSB) in DNA, which are repaired through several DNA repair mechanisms (16 -18) . Defects in DNA repair genes ATM, LIG4, and MRE11 lead to developmental syndromes, all of which show increased radiosensitivity (18, 19) . In vitro, cells with mutations in ATM have been shown to have increased radiosensitivity (20) .
In the treatment of cancer, positive correlations have been made between variants in ATM and radiosensitivity (21 -27) . Such variants have been uncovered by two studies of prostate cancer patients. Hall et al. (25) used DNA sequencing to find ATM mutations in 3 of 17 prostate cancer patients with late radiotherapy side effects. A study of 37 prostate brachytherapy patients by Cesaretti et al. (23) used denaturating highperformance liquid chromatography to identify 21 variants in ATM in 16 patients and found a correlation between possession of sequence variants in this gene, particularly missense variants, and late side effects of prostate brachytherapy. Several studies of this kind have been limited by small sample size, indirect or low-resolution variant detection methods, and examination of only a single candidate gene (21) . Current evidence suggests that radiosensitivity is a complex genetic trait mediated by several genes, each of which may harbor low frequency variants that together modulate the radiosensitive phenotype (21, 27, 28) .
Two studies have examined the role of single nucleotide polymorphisms (SNP) from multiple genes in predicting radiosensitivity of prostate cancer patients treated with radiation. One study genotyped 49 SNPs from 24 genes in 83 patients and identified 3 genes, LIG4, ERCC2, and CYP2D6, containing SNPs associated with radiation toxicity (29) . The second study genotyped 450 SNPs from 118 genes in 197 patients and defined urinary toxicity ''risk genotypes'' associated with SNPs in 5 genes, SART1, ID3, EPDR1, PAH, and XRCC6 (30) . These studies genotyped an average of 1.8 and 6.1 known SNPs from each gene, respectively, and would not have discovered novel variants in these genes that may directly mediate radiosensitivity. To date, no comprehensive sequencing-based survey of multiple candidate DNA repair genes has been done in a set of high and low toxicity prostate brachytherapy patients to discover and genotype such variants.
We set out to perform such a survey to (a) discover new variants and (b) investigate whether variants in genes responsible for detecting and repairing DNA damage contribute to prostate brachytherapy toxicity. To investigate this hypothesis, we sequenced the coding and flanking intronic regions of eight DNA repair genes (ATM, BRCA1, ERCC2, H2AFX, LIG4, MDC1, MRE11A, and RAD50) in 41 prostate cancer patients treated with prostate brachytherapy at the British Columbia Cancer Agency (BCCA). These genes were selected because each plays a role in the detection and repair of DNA damage from ionizing radiation (16 -18) and functional alterations of any of these genes may result in reduced ability to repair double-stranded DNA breaks caused by prostate brachytherapy. Although the effects of radiation can take several forms and involve several mechanisms (31) , late side effects can develop months or years after irradiation due to the presence of unrepaired, damaged DNA. Therefore, we restricted our study to this set of DNA repair genes as the proteins they encode act directly at the site of DSBs and are the primary machinery for the detection and repair of these lesions.
ATM kinase plays a central role as a sensor of DNA damage that activates signal transduction pathways to halt cell cycle progression until the DNA damage is repaired. At the site of a DSB, ATM phosphorylates several proteins including H2AFX, a histone variant, to recruit a nuclease complex for DNA repair (18) . MRE11A nuclease and RAD50 ATPase are part of this complex and enzymatically process the ends of DSBs for repair by homologous recombination (18, 32) . MDC1 mediates the recruitment of this complex by interacting with both H2AFX and MRE11A/RAD50 (32). BRCA1 acts as a scaffold for replication and DNA repair proteins and forms a ''BRCA1-associated genome surveillance complex'' with ATM and the MRE11A/RAD50 complex (18, 33) . LIG4, also known as DNA ligase IV, plays a role in repairing DSBs by uniting broken ends through an alternative mechanism called nonhomologous end joining (18, 34) . Damage to individual DNA bases is addressed by a third mechanism, nucleotide excision repair, in which ERCC2 helicase, also known as XPD, is responsible for unwinding the damaged DNA helical structure so repair can take place (18) .
Methods and Materials
Patient selection and toxicity metrics. The Prostate Brachytherapy Program at the BCCA was established in 1997. As of March 2008, >2,500 patients have undergone prostate brachytherapy as part of this program. Eligible patients included those with low-risk disease (clinical stage VT 2a , initial prostate-specific antigen V10.0 ng/mL, and Gleason score V6) and "low tier" intermediate-risk patients (stage VT 2c and Gleason score V6 with initial prostate-specific antigen 10-15 ng/mL or Gleason score 7 with initial prostate-specific antigen <10 ng/mL). Our implant technique is described in detail elsewhere (3, 4, 6) . Prostate and rectal dosimetry is obtained using day 30 postimplant CT using VariSeed software. Post-implant contouring was done by an implanting oncologist and tissue dosimetry was recorded. Patients are seen at 6 weeks after the procedure, every 6 months for 2 to 3 years, and then annually. Toxicity score components are assessed by physician on each visit: Radiation Therapy Oncology Group (RTOG) urinary and rectal toxicity scores (35) , International Prostate Symptom Score (36) , and erectile function. To better reflect the specific brachytherapy toxicity profile, the genitourinary and gastrointestinal RTOG toxicity scale was modified at the inception of the program.
Translational Relevance
Many genetic studies of radiosensitivity have focused on variants of ATM, a gene central to DNA damage detection and repair, with mixed results. In an expanded search for variants predictive of radiosensitivity, we sequenced the coding and flanking intronic regions of eight DNA repair genes, including ATM, in 41 prostate brachytherapy patients. Through this in-depth survey, genetic variants in three DNA repair genes were identified that may be able to predict late side effects of radiation treatment.Validation of such variants in larger patient populations may lead to prognostic tests to identify radiosensitive cancer patients before treatment. Given such knowledge, the clinical course of these patients could be altered to consider their treatment with nonradiation therapies.
Forty-one prostate brachytherapy patients living in the Vancouver lower mainland region with minimum 3 years of follow-up (mean, 6.6 years) were selected for study from the BCCA Prostate Brachytherapy database, agreed to participate, and provided informed consent. Ethical approval of the study was granted by the BCCA Research Ethics Board. Patients were chosen based on development or lack of development of late normal tissue toxicity following brachytherapy and, to minimize radiation dose as a source of experimental variability, their near-ideal rectal and prostate post-implant dosimetry: prostate D90 <175 Gy (dose covering 90% of the prostate <175 Gy), prostate V100 >85% (volume of the prostate covered by >85% of the radiation dose), and rectal VR100 <1.0 cm 3 (volume of the rectum receiving 145 Gy is <1.0 cm 3 ). Median prostate D90, prostate V100, and rectal VR100 for low and high toxicity patients were 154 Gy, 93%, and 0.26 cm 3 and 148 Gy, 92%, and 0.34 cm 3 , respectively. Although some patients received less than ideal dosimetry, neither the low or high toxicity groups are enriched for these exceptions (P = 1.00 for V100, VR100, and D90) nor is there a linear, exponential, or up to sixth-order polynomial relationship between any of the dosimetry values and toxicity score (R 2 < 0.4). Usually, toxicity after radiation therapy is reported as a single organ or tissue toxicity score and the original RTOG toxicity scale is primarily used for external beam radiation therapy and not for brachytherapy. To adequately capture patients with multiple organ or tissue toxicities, we have created a somewhat arbitrary composite toxicity score listed in Table 1 . Several peerreviewed articles have been published regarding the toxicities determined using the modified RTOG toxicity scores (7 -9) . From our analysis of 1,000 brachytherapy patients with a minimum of 3 years of follow-up, patients with multiple severe toxicities are relatively rare, comprising 2% to 10% of the entire population. 4 For this study, an attempt was made to capture patients with the worse multiple toxicities, respecting the limitation of geographical availability, patient willingness to participate in the study, and self-imposed restrictions related to close to ideal post-implant dosimetry. As acute toxicity is likely related to the prostate brachytherapy procedure itself (4 -6, 9), this study is designed to account for late toxicity only, defined as a development of toxicity >1 year following the implant. The average follow-up time since implant was 78 F 14 months for patients with little or no evidence of late toxicity and 81.2 F 12 months for patients with late toxicity. Twenty patients with no late side effects of prostate brachytherapy were chosen based on a score of 0 or 1 for the criteria listed in Table 1 . Twenty-one patients with documented late side effects to brachytherapy were selected to score in at least two of the Table 1 categories and to have a total score of at least 2. Clinical and DNA sequence variant data used in our analysis for all patients are available in Supplementary Table S1. Supplementary Table S2 contains a summary of the DNA sequence variant data, a breakdown of the toxicity scores, and additional clinical data including hormone usage, tumor stage, planning ultrasound target volume, Gleason score, and age at implant.
PCR amplification and sequencing of DNA repair genes. Each patient provided a 24 mL blood sample from which genomic DNA was extracted using the Gentra Puregene Blood kit (Qiagen) and quantified using a NanoDrop spectrophotometer (NanoDrop Technologies). PCR and sequencing of the target amplicons were carried out by the BCCA Genome Sciences Centre sequencing group using previously published reaction chemistries (37) . PCR volumes were scaled down to 10 AL, 10 ng genomic DNA was used for each reaction, and reactions were done using a 60jC annealing temperature. PCR primer sequences and the genome coordinates of each amplicon are available in Supplementary Table S3 . To facilitate sequencing with universal sequencing primers, each forward primer was ordered with the prefix sequence TGTAAAACGAGGCCAGT and each reverse primer was ordered with the prefix sequence CAGGAAACAGCTATGAC. Variants were detected using Mutation Surveyor version 3.2 (SoftGenetics) and mutation reports were summarized using custom scripts. Genome coordinates and dbSNP accession numbers reported correspond to human genome build 36.1/hg18 (March 2006) and dbSNP build 128. 5 Statistical analysis. Statistical analyses were done using custom Perl and shell scripts. A Perl module implementation of the two-tailed Fisher's exact test 6 was used to assess differences in allele distribution between low and high toxicity patients at each variant site. To investigate the contribution of individual alleles to intrinsic radiosensitivity, four statistical tests were done using different allele distributions between high and low toxicity groups at each variant site (A = reference allele, B = nonreference allele): p1 = AA versus AB + BB, p2 = BB versus AA + AB, p3 = A versus B, and p4 = AA versus BB (heterozygotes discarded). Patients without sequence coverage of a particular variant were not included in the statistical tests of that site. We also used this approach to investigate correlations between these variants and residual gH2AX measured in blood cells from these patients following radiation (38) . We used the combined ranks of the monocyte and lymphocyte scores published by Olive et al. (38) to divide our patients into two groups; 19 ''low gH2AX'' individuals (sum of ranks < 41) and 21 ''high gH2AX'' individuals (sum of ranks z 41). A higher expression of residual gH2AX measured 24 h after radiation can suggest decreased DNA repair capacity and, we hypothesize, an increased likelihood of late side effects. As this is a hypothesisgenerating study seeking to identify subtle genetic relationships with radiosensitivity, we conventionally set our P value threshold for significance at 0.05 with the understanding that false-positives are a real possibility given the number of tests done. More stringent corrections for multiple testing are warranted for future validation studies in larger patient populations.
Results
DNA sequencing summary. We selected eight DNA repair genes in 41 individuals for sequencing. These eight genes contained 173 exons, which were covered by 242 PCR amplicons. The amplicons targeted 115 kbp of genomic sequence, of which 45.2 kbp were exonic (Table 2) . Across 41 patients, 239 sites were shown to differ from the human genome reference sequence and 170 of these corresponded to known variants listed in dbSNP. 7 Sixty of the variants, 14 of them novel, fell in a protein coding region (Table 3 ) and 43 of these result in an amino acid substitution (Table 3) . Twentytwo of the variants that affect an amino acid change are expected to be nonconservative, which we defined as a score <0 on the BLOSUM62 alignment score matrix (39, 40) . Thirty-six variants were small (1-5 bp) insertions or deletions, none of which affected protein coding regions. Twenty-three of these were known polymorphisms recorded in dbSNP, 14 of 25 deletions and 9 of 11 insertions. Variants within exon splicing sites were rare and only a single variant fell within fell within 2 bp of an annotated exon end, a novel intronic MRE11A variant located at chr11:93,866,690 in a single heterozygous low toxicity individual.
The largest gene, ATM, contained the greatest number of variants, 53 in noncoding and 9 in coding regions. However, the 1.5 variants/kbp sequenced was near the average of 2.3 variants/kbp for the eight genes sequenced, suggesting that this gene does not have increased variant density compared with the other genes in our study despite harboring the greatest number of variants. The BRCA1 gene contained the second largest number of variants, 47, and the greatest proportion of known variants recorded in dbSNP, 91%. This likely reflects the intense research interest in this gene due to its association with breast cancer risk. MRE11A and RAD50 contained the lowest number of variants per kbp in coding regions, 0 and 0.3, respectively. This high level of sequence conservation likely reflects the fact that the products of these genes interact with a large number of proteins. In contrast, ERCC2, LIG4, and MDC1 had the greatest number of variants per kbp sequenced, 4.2, 3.6, and 3.7, respectively. Although MDC1 had 23 coding variants, the greatest of any of the genes studied, 5 of these were only present in a single individual with no late side effects (patient 33) and 4 were shared exclusively between this individual and a patient with high toxicity (patient 43). H2AFX, the smallest gene, contained the fewest number of variants, 5, and the single coding variant, although novel, did not result in an amino acid change.
ATM variants detected by previous studies of radiosensitivity. We detected five known coding variants observed in previous studies relating ATM to radiosensitivity: (a) 2119T>C, P707S The first and second variants, resulting in amino acid changes S707P and D1853V, respectively, were observed in a single low toxicity patient heterozygous at both sites. The third variant, resulting in the amino acid change P1045R, has been found previously to double the risk of developing prostate cancer (41) and was observed in two heterozygous high toxicity patients in our population (patients 9 and 17). The fourth variant, a synonymous change retaining P1526, was observed in two heterozygous patients, one with high toxicity and one with low toxicity. The fifth variant, resulting in the amino acid change D1853N and suggested previously to mediate radiosensitivity in breast cancer patients (22) , was observed in five heterozygous patients, three low toxicity and two high toxicity. None of these variants were statistically associated with high prostate brachytherapy toxicity in our population (P > 0.46).
Using quantity of DNA repair gene variants to predict radiosensitivity. Previous studies have postulated that the number of variants in a DNA repair gene can be used to distinguish radiotherapy patients with high toxicity from low toxicity (22 -24, 30) . In our study, every patient had at least one variant in each of five DNA repair genes (ATM, ERCC2, H2AFX, MDC1, and RAD50; Fig. 1 ). Three genes had more variants on average in the high toxicity patients than in the low toxicity patients (BRCA1, H2AFX, and MDC1). However, there was no statistically significant enrichment to either side of the mean in high or low toxicity groups for any of the eight genes studied (P > 0.10). This was also true for missense variants (P > 0.09) and nonconservative variants (P > 0.16). However, when all coding variants were taken as a group regardless of amino acid conservation score, we did observe an enrichment of such variants in the LIG4 gene in high toxicity patients (P = 0.03 for LIG4 and P > 0.34 for all other genes). We tested all possible quantity thresholds (from 1 to 32 variants) of all four variant classes to distinguish low toxicity and high toxicity groups and found only one that met statistical significance. In our population, the high toxicity group was enriched for individuals harboring at least one LIG4 coding variant.
Using specific DNA repair gene variants to predict radiosensitivity. We hypothesized that specific DNA repair gene variants, not the number of such variants, would be associated with radiosensitivity. To assess genetic associations with radiation toxicity, the genotype and allele distribution between high and low toxicity groups were analyzed at every variant site using four two-tailed Fisher's exact tests (Materials and Methods). One coding synonymous variant in MDC1 , 4178C>CG, A1657AA, located at chr6:30,779,968, returned a P < 0.05 (p1 = 0.048, p2 = 1.00, p3 = 0.056, and p4 = 1.00). All five patients with the minor allele (patients 4, 18, 21, 26 , and 34) were heterozygous and had high radiation toxicity scores (6, 3, 4, 5, and 13). This variant has been previously recorded in dbSNP as rs28986317 and minor allele frequencies have been observed from 1% to 6% in four populations. All other variant sites returned P values > 0.05 and none appeared to be associated with increased radiation toxicity at a statistically significant level in our patient population.
Relationship of DNA repair gene variants with residual gH2AX following irradiation. Assessments of DNA repair ability, represented by the relative expression of gH2AX remaining 24 h after exposure to 2 Gy, were taken for 40 of 41 of the patients (38) . Although residual gH2AX following irradiation did not correlate with late side effects of prostate brachytherapy (38), we did observe 15 intronic variants to be correlated with decreased residual gH2AX (increased DNA repair activity; P V 0.049) and 1 coding, missense variant to be correlated with increased residual gH2AX (decreased DNA repair ability; P = 0.042; Table 4 ). Fourteen of the 15 low gH2AX variants were in BRCA1, and 13 of these were documented in dbSNP, suggesting a primary role for this protein in addressing DSBs marked by gH2AX. The remaining intronic variant is a known variant in MDC1 (rs9405048), but none of these variants were correlated with fewer late side effects of prostate brachytherapy (P z 0.127). The single variant associated with increased gH2AX results in a conservative amino acid change in ERCC1 (D312N, BLOSUM62 score = 1) and is documented in dbSNP (rs1799793). Twelve of the 17 patients harboring the minor allele had high expression of residual H2AX (sum of ranks z 41) and 5 of these had toxicity scores >2. Patient 10 was an exception as he harbored the minor allele and received a high toxicity score of 7 and yet had the lowest residual gH2AX. This patient did not harbor any of the 15 variants correlated with decreased gH2AX, suggesting that clearance of DSBs is also mediated by genes outside of our candidate set.
Discussion
To the best of our knowledge, this study represents the first direct sequencing study of multiple DNA repair genes in radiosensitive and radiotolerant prostate brachytherapy patients. This survey uncovered 239 variants distributed across eight DNA repair genes, of which 69 were novel and had not been recorded in dbSNP. Of the 46 coding variants, 32 of which resulted in an amino acid change, 14 were not in dbSNP. These results suggest that the genetic diversity of these genes is not fully captured in existing databases and that sequencing of genes in larger populations is necessary to uncover lower frequency variants that may define complex radiosensitive phenotypes.
This survey identified five ATM variants analyzed in previous investigations of ATM and radiosensitivity (22 -24, 26 ) but observed no statistically significant relationship with late side effects of prostate brachytherapy. Contrary to previous reports (23, 24) , the number of variants in ATM could not predict radiation toxicity. However, a specific variant that doubles the Fig. 1 . Toxicity scores, radiation dosimetry, count of DNA variants, and gH2AX rank expression from 41prostate brachytherapy patients. X axis, patient numbers ordered by toxicity score (top). This panel indexes the subsequent panels and shows the toxicity score for each patient determined using the scoring system shown inTable 1. Dashed vertical line (middle) separates data of low toxicity patients (left ; toxicity score V1) from high toxicity patients (right ; toxicity score >1). The next three panels present similar post-implant radiation dosimetry for each patient. Dashed red lines, thresholds for ''ideal''dosimetry (D90 <175 Gy,V100 >85%, and VR100 <1cm ). Panels 5 to 12, number of all variants (black, left axis) and coding variants (red, right axis) in each gene from each patient. Genes are ordered first by the magnitude of the left Yaxis (the maximum count of total variants) and then by the magnitude of the right Yaxis (the maximum count of coding variants). Note the enrichment of individuals with at least one LIG4 coding mutation in high versus low toxicity individuals (P = 0.028). Counts that include specific variants associated with radiosensitivity, ATM rs1800057 (P1054R) and MDC1 rs28986317, are indicated by wireframe data markers.The last panel displays sum of rank data from Olive et al. (38) and represents the combined rank of residual gH2AX scores from lymphocytes and monocytes from 40 of the 41patients. The numbers used to generate these plots are available in SupplementaryTable S3. Lines between each point are for ease of comparison and do not represent continuous variables or an explicit relationship between data points. risk of prostate cancer, P1054R (41), was seen exclusively in two high toxicity individuals, which suggests that aspects of DNA repair ability may underlie a predisposition for prostate cancer. Although the frequency of this variant in the high toxicity group did not reach statistical significance (P = 0.488), the fact that this variant was found exclusively in high toxicity patients warrants further investigation in larger populations as a potential predictor of radiosensitivity. Of 239 variants detected across eight DNA repair genes, only one variant, rs28986317 in MDC1, was statistically associated with late side effects of prostate brachytherapy (P = 0.048). The biological effect of this variant on protein structure is not immediately obvious, as it does not result in an amino acid change. However, synonymous changes have been shown to affect protein translation due to changes in codon usage, altered mRNA stability, disrupted miRNA binding, and exon skipping (42) .
Despite representing <10% of the sequence targeted, coding variants in MDC1 represented >33% of the synonymous variants, >25% of the conservative variants, and >50% of the nonconservative variants, including all of the novel nonconservative variants detected in our study. The large amount of perkbp variation present in this gene and others may explain the wide range of toxicities observed following radiation treatment. In the case of MDC1, a recruiter of DNA damage repair complexes, different variants may preferentially recruit complexes specific to each individual. Similarly, the high number of variants per kbp in ERCC2 and LIG4, proteins that directly carry out repair, may reflect a spectrum of activation efficiencies or enzymatic activities that manifest as a range of toxicity levels.
Our study's small patient population limits the statistical power of our analysis to resolve cumulative genetic effects on radiosensitivity at a population level. Regardless, even from this small population, a large amount of genetic diversity was observed in the eight candidate genes sequenced. The positive results associating the MDC1 variant with increased radiosensitivity and the observation of the ATM variant P1054R exclusively in high toxicity patients need to be validated in larger populations particularly as no correction for multiple testing was done and there is a possibility of false-positives. The finding that no single LIG4 variant was statistically associated with radiosensitivity despite the observation that high toxicity patients were more likely to contain LIG4 coding variants suggests that this gene may contain a class of low frequency variants with similar effect on protein behavior. As LIG4 functions as a ligase, variants resulting in codon or amino acid substitutions in this protein may decrease its ability to join broken ends of DNA or reduce the amount of enzyme available to perform DNA repair.
Variants in DNA repair genes were both positively and negatively associated with residual gH2AX that signifies the presence of unrepaired or misrepaired DSBs following irradiation (38) . Noncoding variants, 14 in BRCA1 and 1 in MDC1 correlated with lower levels of gH2AX (P V 0.049), whereas a coding, nonsynonymous variant in ERCC2 (rs1799793) was correlated with higher levels of gH2AX (P = 0.042; Table 4 ). The ERCC2 minor allele was found in 42% of patients (5 of 12) with high levels of residual gH2AX and high toxicity. Whereas gH2AX levels did not correlate with development of late side effects of prostate brachytherapy (38) , variants in specific DNA repair genes, particularly BRCA1 and ERCC1, appear to mediate the clearance of DSBs, which may play a factor in the eventual development of toxicity.
This initial survey has identified several promising candidate variants that may show an ability to predict increased radiosensitivity in a larger population and serves to illustrate the genetic diversity present in several DNA repair genes. Although the hypothesis that DNA repair gene variants mediate radiosensitivity has not been disproven, it is likely that variants outside of this set of candidate genes may also play a role in mediating radiosensitivity.
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